None listed
Conditions
Interventions
Drug : 1. Single-Dose Group: One Hytrin 5mg tablet is administered before bed with QD dose for 12 weeks.
2. Concommitant Group: One Hytrin 5mg tablet is administered before bed with QD dose for 12week
Sponsors
Chung-Ang Univerisity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female over 20 years old 2. Patients who have urination volume more than 100ml due to dysuria
Exclusion criteria
Exclusion criteria: 1. Patients with urinary tract stones, urethral strictures or urinary tract infections 2. Patients with prostate cancer or who have undergone prostate surgery 3. Patients who underwent surgery due to bladder stenosis or enlarged prostate 4. Patients diagnosed with cardiovascular disease, liver disease, orthostatic hypotension or renal dysfunction 5. Patients taking cholinesterase, anticholinergics, alpha antagonists and agonists, beta antagonists and agonists, 5-alpha reductase inhibitors 6. Patients with urinary epithelium malignancies 7. Patients who are not able to participate in this clinical trial at the discretion of the other investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of symptom improvement by International Prostate Symptom Score(IPSS) test | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of variance of Post-void Volume of Residual urine;Comparison of drug efficacy among each group by gender(International Prostate Symptom Score, Post-void Volume of Residual urine) | — |
Countries
Korea, Republic of
Contacts
Public ContactTae Hyung Kim
Chung-Ang University
Outcome results
None listed